Elfabrio (pegunigalsidase alfa-iwxj) IV for Fabry disease
Outlines prior authorization, initial and renewal clinical criteria, dosing, HCPCS/NDC coding, authorization lengths, and covered diagnosis for Elfabrio (pegunigalsidase alfa-iwxj) administered intravenously for treatment of Fabry disease.
Document lists review dates 06/2023, 02/2024, 04/2025, 04/2026 and retains prior authorization length and criteria.
Coverage Summary
Covered with criteria for IV Elfabrio (pegunigalsidase alfa-iwxj) for Fabry disease; prior authorization required with initial authorization valid for 12 months (365 days) and may be renewed every 12 months (365 days). Scope includes prior authorization, initial and renewal clinical criteria, dosing, HCPCS/NDC coding, authorization lengths, and covered diagnosis for Elfabrio administered intravenously. Effective date: 2023-06-01; Last review: 2026-04-01.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.